D
Exagen Inc.
XGN
$3.35
$0.020.60%
D
Sell
8/16/2024Upgraded
Exagen Inc. (XGN) was upgraded to D- from E+ on 8/16/2024 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 73.16% from -$9.04M to -$2.43M, EBIT increased 13.85% from -$3M to -$2.59M, and earnings per share increased from -$0.1872 to -$0.1632.
Exagen Inc. (XGN) was upgraded to D- from E+ on 8/16/2024 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 73.16% from -$9.04M to -$2.43M, EBIT increased 13.85% from -$3M to -$2.59M, and earnings per share increased from -$0.1872 to -$0.1632.
E
Sell
10/19/2023Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D- on 10/19/2023 due to a decline in the volatility index and total return index.
Exagen Inc. (XGN) was downgraded to E+ from D- on 10/19/2023 due to a decline in the volatility index and total return index.
D
Sell
10/3/2023Upgraded
Exagen Inc. (XGN) was upgraded to D- from E+ on 10/3/2023 due to an increase in the volatility index.
Exagen Inc. (XGN) was upgraded to D- from E+ on 10/3/2023 due to an increase in the volatility index.
E
Sell
9/14/2023Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D- on 9/14/2023 due to a decline in the volatility index and total return index.
Exagen Inc. (XGN) was downgraded to E+ from D- on 9/14/2023 due to a decline in the volatility index and total return index.
D
Sell
8/28/2023Upgraded
Exagen Inc. (XGN) was upgraded to D- from E+ on 8/28/2023 due to an increase in the volatility index and total return index.
Exagen Inc. (XGN) was upgraded to D- from E+ on 8/28/2023 due to an increase in the volatility index and total return index.
E
Sell
8/9/2023Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D- on 8/9/2023 due to a decline in the volatility index.
Exagen Inc. (XGN) was downgraded to E+ from D- on 8/9/2023 due to a decline in the volatility index.
D
Sell
7/31/2023Upgraded
Exagen Inc. (XGN) was upgraded to D- from E+ on 7/31/2023 due to an increase in the volatility index.
Exagen Inc. (XGN) was upgraded to D- from E+ on 7/31/2023 due to an increase in the volatility index.
E
Sell
7/12/2023Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D- on 7/12/2023 due to a decline in the volatility index.
Exagen Inc. (XGN) was downgraded to E+ from D- on 7/12/2023 due to a decline in the volatility index.
D
Sell
6/23/2023Upgraded
Exagen Inc. (XGN) was upgraded to D- from E+ on 6/23/2023 due to an increase in the total return index and volatility index.
Exagen Inc. (XGN) was upgraded to D- from E+ on 6/23/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D- on 03/14/2023.
Exagen Inc. (XGN) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Exagen Inc. (XGN) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Exagen Inc. (XGN) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 8.46 to 7, and debt to equity increased from 0.47 to 0.53.
Exagen Inc. (XGN) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 8.46 to 7, and debt to equity increased from 0.47 to 0.53.
D
Sell
8/8/2022Downgrade
Exagen Inc. (XGN) was downgraded to D- from D on 8/8/2022 due to a decline in the growth index, solvency index and volatility index. EBIT declined 31.29% from -$9.68M to -$12.71M, operating cash flow declined 30.09% from -$8.57M to -$11.15M, and earnings per share declined from -$0.6045 to -$0.7802.
Exagen Inc. (XGN) was downgraded to D- from D on 8/8/2022 due to a decline in the growth index, solvency index and volatility index. EBIT declined 31.29% from -$9.68M to -$12.71M, operating cash flow declined 30.09% from -$8.57M to -$11.15M, and earnings per share declined from -$0.6045 to -$0.7802.
D
Sell
7/28/2022Upgraded
Exagen Inc. (XGN) was upgraded to D from D- on 7/28/2022 due to an increase in the volatility index and total return index.
Exagen Inc. (XGN) was upgraded to D from D- on 7/28/2022 due to an increase in the volatility index and total return index.
D
Sell
7/13/2022Downgrade
Exagen Inc. (XGN) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index and total return index.
Exagen Inc. (XGN) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index and total return index.
D
Sell
6/24/2022Upgraded
Exagen Inc. (XGN) was upgraded to D from D- on 6/24/2022 due to an increase in the volatility index.
Exagen Inc. (XGN) was upgraded to D from D- on 6/24/2022 due to an increase in the volatility index.
D
Sell
6/9/2022Downgrade
Exagen Inc. (XGN) was downgraded to D- from D on 6/9/2022 due to a decline in the total return index and volatility index.
Exagen Inc. (XGN) was downgraded to D- from D on 6/9/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Exagen Inc. (XGN) was upgraded to D from E+ on 05/16/2022.
Exagen Inc. (XGN) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, solvency index and total return index. EBIT declined 54.76% from -$6.25M to -$9.68M, earnings per share declined from -$0.4156 to -$0.6045, and operating cash flow declined 41.79% from -$6.05M to -$8.57M.
Exagen Inc. (XGN) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, solvency index and total return index. EBIT declined 54.76% from -$6.25M to -$9.68M, earnings per share declined from -$0.4156 to -$0.6045, and operating cash flow declined 41.79% from -$6.05M to -$8.57M.
D
Sell
4/21/2022Upgraded
Exagen Inc. (XGN) was upgraded to D from E+ on 04/21/2022.
Exagen Inc. (XGN) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Exagen Inc. (XGN) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 14.33 to 11.71, and debt to equity increased from 0.31 to 0.33.
Exagen Inc. (XGN) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 14.33 to 11.71, and debt to equity increased from 0.31 to 0.33.
D
Sell
11/15/2021Upgraded
Exagen Inc. (XGN) was upgraded to D from D- on 11/15/2021 due to an increase in the valuation index, total return index and volatility index.
Exagen Inc. (XGN) was upgraded to D from D- on 11/15/2021 due to an increase in the valuation index, total return index and volatility index.
D
Sell
11/8/2021Downgrade
Exagen Inc. (XGN) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Exagen Inc. (XGN) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
10/1/2020Upgraded
Exagen Inc. (XGN) was upgraded to D from D- on 10/1/2020 due to an increase in the growth index. Earnings per share increased from -$0.4417 to -$0.2661, and EBIT increased 31.95% from -$5.02M to -$3.42M.
Exagen Inc. (XGN) was upgraded to D from D- on 10/1/2020 due to an increase in the growth index. Earnings per share increased from -$0.4417 to -$0.2661, and EBIT increased 31.95% from -$5.02M to -$3.42M.
D
Sell
6/2/2020Upgraded
Exagen Inc. (XGN) was upgraded to D- from E on 6/2/2020 due to an increase in the efficiency index and valuation index.
Exagen Inc. (XGN) was upgraded to D- from E on 6/2/2020 due to an increase in the efficiency index and valuation index.
E
Sell
4/30/2020Downgrade
Exagen Inc. (XGN) was downgraded to E from E+ on 4/30/2020 due to a decline in the total return index, volatility index and valuation index.
Exagen Inc. (XGN) was downgraded to E from E+ on 4/30/2020 due to a decline in the total return index, volatility index and valuation index.
E
Sell
3/27/2020Upgraded
Exagen Inc. (XGN) was upgraded to E+ from E on 3/27/2020 due to an increase in the valuation index.
Exagen Inc. (XGN) was upgraded to E+ from E on 3/27/2020 due to an increase in the valuation index.
E
Sell
3/17/2020Downgrade
Exagen Inc. (XGN) was downgraded to E from E+ on 3/17/2020 due to a decline in the valuation index and volatility index.
Exagen Inc. (XGN) was downgraded to E from E+ on 3/17/2020 due to a decline in the valuation index and volatility index.
E
Sell
3/2/2020Upgraded
Exagen Inc. (XGN) was upgraded to E+ from E on 3/2/2020 due to an increase in the valuation index.
Exagen Inc. (XGN) was upgraded to E+ from E on 3/2/2020 due to an increase in the valuation index.
E
Sell
2/12/2020Upgraded
Exagen Inc. (XGN) was upgraded to E from E- on 2/12/2020 due to a noticeable increase in the total return index and valuation index.
Exagen Inc. (XGN) was upgraded to E from E- on 2/12/2020 due to a noticeable increase in the total return index and valuation index.
E
Sell
12/24/2019Downgrade
Exagen Inc. (XGN) was downgraded to E- from E on 12/24/2019 due to a decline in the valuation index.
Exagen Inc. (XGN) was downgraded to E- from E on 12/24/2019 due to a decline in the valuation index.
E
Sell
12/12/2019None
Exagen Inc. (XGN) was downgraded to E from U on 12/12/2019.
Exagen Inc. (XGN) was downgraded to E from U on 12/12/2019.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
